These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16480245)

  • 81. Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data.
    Bushe C; Leonard B
    Br J Psychiatry Suppl; 2004 Apr; 47():S87-93. PubMed ID: 15056600
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Acute cholestatic hepatitis probably associated with risperidone.
    Llinares Tello F; Hernández Prats C; Bosacoma Ros N; Pérez Martínez E; Climent Grana E; Navarro Polo JN; Ordovás Baines JP
    Int J Psychiatry Med; 2005; 35(2):199-205. PubMed ID: 16240976
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Glucose metabolism, schizophrenia, and antipsychotic drugs: comments to the paper of Dwyer et al.
    Baptista T; Beaulieu S
    Ann Clin Psychiatry; 2001 Dec; 13(4):241-2. PubMed ID: 11958367
    [No Abstract]   [Full Text] [Related]  

  • 84. Are patients with schizophrenia treated less with second-line glucose-lowering drugs for type 2 diabetes?
    Jacobsen SL; Köhler-Forsberg O; Rohde C
    Schizophr Res; 2024 Aug; 270():231-234. PubMed ID: 38936114
    [No Abstract]   [Full Text] [Related]  

  • 85. Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications.
    Cavazzoni P; Mukhopadhyay N; Carlson C; Breier A; Buse J
    Br J Psychiatry Suppl; 2004 Apr; 47():S94-101. PubMed ID: 15056601
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Metformin for Antipsychotic-Related Metabolic Syndrome in Children: Fact or Fiction?
    Naguy A; El-Sori D
    Chin Med J (Engl); 2018 Jun; 131(12):1490-1491. PubMed ID: 29893366
    [No Abstract]   [Full Text] [Related]  

  • 87. Improvement of type 2 diabetes in a bipolar patient after initiation of atypical antipsychotic therapy.
    Claro AE; Palanza C; Mazza M; Rizzi A; Tartaglione L; Marano G; Muti Schuenemann GE; Rigoni M; Muti P; Pontecorvi A; Janiri L; Sani G; Pitocco D
    Minerva Endocrinol (Torino); 2024 Jun; 49(2):226-228. PubMed ID: 35912669
    [No Abstract]   [Full Text] [Related]  

  • 88. [Atypical antipsychotics: new etiology in type 2 diabetes mellitus].
    Flores Meneses L; Sanmartí Sala A
    Med Clin (Barc); 2005 Mar; 124(9):341-3. PubMed ID: 15760602
    [No Abstract]   [Full Text] [Related]  

  • 89. Schizophrenia and diabetes mellitus.
    Mohan D; Gordon H; Hindley N; Barker A
    Br J Psychiatry; 1999 Feb; 174():180-1. PubMed ID: 10211179
    [No Abstract]   [Full Text] [Related]  

  • 90. More evidence of an association between antipsychotic drugs and the risk of diabetes in children and adolescents: a population-based study.
    Bobo WV
    Evid Based Ment Health; 2015 May; 18(2):e1. PubMed ID: 25743447
    [No Abstract]   [Full Text] [Related]  

  • 91. Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis.
    Speyer H; Westergaard C; Albert N; Karlsen M; Stürup AE; Nordentoft M; Krogh J
    Front Endocrinol (Lausanne); 2021; 12():577919. PubMed ID: 34393989
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Treatment of Diabetic Ketoacidosis Associated With Antipsychotic Medication: Literature Review.
    Vuk A; Baretic M; Osvatic MM; Filipcic I; Jovanovic N; Kuzman MR
    J Clin Psychopharmacol; 2017 Oct; 37(5):584-589. PubMed ID: 28816925
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Atypical antipsychotics and diabetic ketoacidosis: a review.
    Guenette MD; Hahn M; Cohn TA; Teo C; Remington GJ
    Psychopharmacology (Berl); 2013 Mar; 226(1):1-12. PubMed ID: 23344556
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
    Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [The appearance of metabolic syndrome in treatment with atypical antipsychotics].
    Mosolov SN; Kabanov SO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):62-9. PubMed ID: 14681970
    [No Abstract]   [Full Text] [Related]  

  • 97. Diabetes associated with atypical antipsychotic treatment may be severe but reversible: case report.
    Dibben CR; Kalavalapalli SS; Linnington HE; Hynes FA; Dinneen SF; Adler AI; McKenna PJ
    Int J Psychiatry Med; 2005; 35(3):307-11. PubMed ID: 16480245
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
    Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
    Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
    [TBL] [Abstract][Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.